Bryan Johnson, the 46-year-old tech millionaire, has added a new and controversial dimension to his quest for longevity by undergoing gene therapy that has not been approved by the FDA. Johnson, known for his ambitious Project Blueprint aimed at reversing his biological age, recently revealed on Instagram that he had his first round of follistatin therapy in September.
Protein called follistatin, which is said to increase muscle mass and decrease inflammation, costs an astounding $25,000 each dosage. Interestingly, the FDA has not approved it, and some scientists are still unsure about its effectiveness. The biotech business Minicircle, which has the financial backing of prominent individuals including billionaire Peter Thiel and CEO of OpenAI Sam Altman, is providing the therapy. The business hasn’t yet made data from clinical trials public, though.
Johnson enthusiastically shared his experience on social media, declaring himself a “genetically enhanced human (GEH).” Despite the hefty price tag, Minicircle’s co-founder informed Bloomberg that Johnson is not being charged, suggesting he is providing something of greater value to the company.
The tech mogul has been investing approximately $2 million annually in his anti-aging pursuits, with Project Blueprint boasting a team of doctors who claim to have transformed his skin to that of a 28-year-old, his heart to that of a 37-year-old, and his lung capacity to that of an 18-year-old. However, these assertions remain unverified, contributing to the ongoing debate surrounding the concept of “biological age.”
Bryan Johnson’s quest for immortality in 2020 took a serious turn, resulting in major lifestyle adjustments such as giving up junk food and late nights and switching to a vegan diet. In his never-ending search for the elixir of youth, the businessman, who gained notoriety for creating Braintree, a payments processing company that he later sold to eBay for $800 million in 2013, is pushing the limits of traditional medical procedures.
